Peptide blend of GHK-Cu, BPC-157, and TB-500, studied for skin quality, tissue repair, and recovery.
This is a combination sold as one vial. It has not been studied as a single substance, so what is known is what is known about each part, linked above. Sources that report a dose for the blend report it for that mixture, not for any component on its own.
We have not published an audit on GLOW. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.
Combines copper peptide (GHK-Cu) with repair peptides (BPC-157, TB-500); studied for skin, tissue repair, and recovery.
GLOW combines three peptides: BPC-157 promotes new blood vessel growth at injury sites, TB-500 helps repair cells migrate to where they are needed, and GHK-Cu supports collagen and elastin synthesis for better tissue quality and matrix remodeling.
Side effects are generally mild and may include injection-site irritation, short-term fatigue during TB-500 loading, occasional headache, and a slight metallic sensation at the injection site from GHK-Cu; copper accumulation is a concern with prolonged GHK-Cu use, which is why cycling is recommended.
People with active cancer or vascular disorders are advised to avoid GLOW because BPC-157 and TB-500 both promote blood vessel growth, and competitive athletes should avoid it as BPC-157 and TB-500 are WADA-prohibited.
COA (Certificate of Analysis) verification from suppliers is named; an at-home blood test (SiPhox Health) is listed as a supply item. The page advises reassessing if injection-site reactions worsen, fatigue persists past the loading phase, or any unusual symptoms occur, but no specific lab panels are named. [Source: peptidedosingprotocols.com]
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for GLOW or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| 10 units (0.10 mL) daily, approximately 2.33 mg total blend. | not stated | not stated | Peptide Dosing Protocols stackWhat it saysHide(secondary reference; provider confirmation required). |
| Pre-blend: 0.10 mL (10 units) daily = ~2.33 mg total blend (~1.67 mg GHK-Cu, ~0.33 mg TB-500, ~0.33 mg BPC-157). Separate vials: BPC-157 250-500 mcg/day; TB-500 2.5-5 mg per injection 2x/week (loading), 2 mg per injection (maintenance); GHK-Cu 1-2 mg/day (loading), 1 mg/day (maintenance). | Once daily (pre-blend); separate vials: BPC-157 daily, TB-500 twice weekly, GHK-Cu dailyStandard: 4-6 weeks on, 2-4 weeks off; Extended: 8-12 weeks on, 4-8 weeks off; Skin-focused blend: 4 weeks on, 2-4 weeks off. GHK-Cu copper cycling typically governs cycle length: 30-60 days on, equal time off. | subcutaneous | peptidedosingprotocols.comWhat it saysHide(secondary reference; provider confirmation required). [Source: peptidedosingprotocols.com] |
GLOW peptide is a research blend of three compounds — BPC-157, TB-500, and GHK-Cu — usually sold pre-blended at a 5:1:1 GHK-Cu-dominant ratio. It pairs the soft-tissue repair coverage of BPC-157 and TB-500 with the collagen and matrix-quality remodeling tied to GHK-Cu.
Most pre-blended GLOW products contain 50 mg GHK-Cu, 10 mg TB-500, and 10 mg BPC-157 in a single 70 mg vial — the 5:1:1 ratio that makes GLOW GHK-Cu-dominant.
Compound-level research most associates the GLOW combination with soft-tissue repair coverage, collagen and skin-quality remodeling driven by GHK-Cu, anti-inflammatory pathway overlap, and organized matrix formation. There is no published human trial of the three compounds together.
The most common pre-blended schedule is 0.10 mL (10 units) once daily from a 70 mg vial reconstituted with 3 mL bacteriostatic water. That delivers about 1.67 mg GHK-Cu, 0.33 mg TB-500, and 0.33 mg BPC-157 per injection. Separate-vial schedules use 250–500 mcg BPC-157 daily, 2.5–5 mg TB-500 twice weekly, and 1–2 mg GHK-Cu daily.
Open the reconstitution calculator →For a 70 mg pre-blend vial, add 3 mL of bacteriostatic water against the inside of the glass — do not aim it at the powder. Roll gently for 30–60 seconds. The result is a 23.3 mg/mL total-blend concentration. For separate vials, each compound is reconstituted on its own.
Check 70 mg in 3 mL in the calculator →Standard community-protocol cycles run 4–6 weeks on with 2–4 weeks off. GHK-Cu copper cycling typically governs the on/off schedule — most workflows match the GLOW cycle to GHK-Cu's 30–60 days on, equal time off pattern.
Wolverine is just BPC-157 + TB-500 — two compounds focused on repair. GLOW adds GHK-Cu, which brings collagen and skin-quality remodeling into the protocol. GLOW is more complex and costs more; Wolverine is simpler and repair-only.
The most commonly reported effects are mild injection-site irritation, short-term fatigue during TB-500 loading, and occasional headache. The main stack-specific consideration is overlap of angiogenic signaling from BPC-157 and TB-500, which is why people with active cancer or vascular disorders are advised to avoid these compounds.
The reference sections above are imported from our compound knowledge base, which classes the evidence for GLOW as emerging. That classification is the knowledge base’s, not ours, our own grade appears only where an audit is linked above. Research use only; nothing here is medical advice or a protocol.
BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in gastric juice. Studied in tissue-repair and regeneration research models.
5-Amino-1MQ is a small molecule studied for its potential to help the body shrink fat cells and raise NAD+ levels without cutting appetite.
Peptide bioregulator referenced for connective tissue support.
Peptide bioregulator referenced for nervous system support.
Combination research blend of CJC-1295 (no DAC) and Ipamorelin. Studied as a GHRH/GHRP combination in growth-hormone-axis research.
Peptide bioregulator referenced for pineal support.